|
Dear Colleagues,
Welcome to our December 2011 issue of Science Speaks!.
This month's issue features a summary of our course on cultural adaptation in clinical trials taught by our life science expert, how Indian generics are dominating the US market, foreign medical device approved in Japan, and a new drug registration law in Russia.
Visit our website at www.languageconnections.com for more information about our services or to read more of our life science articles.
Enjoy!
|
|
LC Lectures on Cultural Adaptation in Trials
|
|
Language Connections was recently invited to participate in teaching an online course called "Principles of Transcultural Health Care" as part of a master's degree program at the University of Medicine & Dentistry of New Jersey. The program is part of a new Bio Pharma Educational Initiative which is offered throughout the university.
The session given by our life science expert Karen Politis Virk, entitled 'Cultural Adaptation in Clinical Trials', primarily deals with the logistics of overcoming linguistic and cultural barriers among increasingly diverse patient populations.
Read more...
|
|
Indian Generics Dominate US Market
|
|
The Indian phamaceutical company Glenmark Pharmaceuticals recently launched their malaria drug treatment in the US which is the generic equivalent of GlaxoSmithKline's brand anti-malarial drug Malarone.
With Pfizer's cholesterol-lowering blockbuster Lipitor going off patent, another Indian generics company, Ranxbury, is hoping to corner that market.
Many Indian generic companies have gotten product approval recently in US - in fact this year Indian companies account for 35% of abbreviated drug applications in the US.
Read more...
|
|
We are very pleased to share our newsletter with you. If you have any inquiries, comments, or suggestions, please contact us or visit our website at www.languageconnections.com! Sincerely,
Leo Galperin, President
Language Connections
Boston, MA
Tel. 617-731-3510
|